Skip to main content
Article thumbnail
Location of Repository

Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia

By Philip E Lee, Sudeep S Gill and Paula Rochon

Abstract

Neuropsychiatric symptoms are common in older adults with dementia and can be associated with a rapid decline in cognitive and functional status. This article reviews the current literature supporting the use of atypical antipsychotic medications in this population. Among the currently available atypical antipsychotics, risperidone and olanzapine have been the most widely studied in double-blind, randomized, placebo-controlled clinical trials. Despite the common use of other atypical antipsychotic medications, their efficacy and safety in older adults with dementia has not been as extensively studied. Some controversy surrounds the use of atypical antipsychotic agents in older adults with the suggestion that they may increase the incidence of stroke or even death. Despite the potential for increased risk of harm from the use of these medications, atypical antipsychotics are often effective in treating troublesome neuropsychiatric symptoms refractory to other treatments. Whenever possible, these atypical antipsychotic drug treatments should be combined with non-pharmacological treatments to limit the need and dose of antipsychotic drugs and constant monitoring for potential harms should be maintained. The choice of which atypical antipsychotic agent can be guided by the nature and severity of the target symptom and the medication least likely to cause harm to the patient

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2671943
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2004). 14:484–7.Neuropsychiatric Disease and Treatment 2006:2(4) 528 Lee et al Fernandez HH,
    2. (2001). 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychoticinduced cortical dopamine release.
    3. (2000). A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.
    4. (2003). A randomized placebocontrolled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia,
    5. (1999). A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.
    6. (2005). A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.
    7. (2005). Administrative initiatives for reducing inappropriate prescribing of psychotropic drugs in nursing homes: how successful have they been?. Drugs Aging,
    8. (1986). Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated.
    9. (2002). An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.
    10. (1989). An observational study of agitation in agitated nursing home residents. Int Psychogeriatr,
    11. (2001). Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev,
    12. (2005). Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults.
    13. (2001). Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging,
    14. (2005). Aripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: a randomized, placebo-controlled study.
    15. (2005). Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study.
    16. (2004). Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review.
    17. (2005). Atypical antipsychotic therapy and hyperlipidemia: a review. Essent Psychopharmacol,
    18. (2005). Atypical antipsychotics and parkinsonism,
    19. (1987). Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment.
    20. (1994). Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations.
    21. (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.
    22. (2005). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
    23. (2000). Clozapine and risperidone treatment of psychosis in Parkinson’s disease.
    24. (2004). Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up.
    25. (2003). Clozapine in Parkinson’s disease psychosis: 5-year follow-up review. Clin Neuropharmacol,
    26. (2003). Coma with accidental single dose of an atypical neuroleptic in a patient with Lewy Body dementia.
    27. (2004). Committee on Safety of Medications–Atypical antipsychotic drugs and stroke.
    28. (2001). Committee on Safety of Medicines/Medicines Control Agency.
    29. (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
    30. (1999). Conventional vs. newer antipsychotics in elderly patients.
    31. (2002). Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
    32. (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    33. (1998). Efficacy and safety of neuroleptics in behavioral disorders associated with dementia.
    34. (2000). Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry,
    35. (2004). Ethnic differences in the prevalence and pattern of dementia-related behaviors.
    36. (2004). European Agency for the Evaluation of Medicinal Products (EMEA. Cerebrovascular events and increased mortality in eldery patients with dementia.
    37. (2003). Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults.
    38. (2006). FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances [online].
    39. (2006). Health Canada advises consumers about important safety information on atypical antipsychotic drugs and dementia [online]. Accessed 7April
    40. (1999). Health resource utilization and clinical outcomes with risperidone therapy in patients with serious mental illness. Compr Psychiatry,
    41. (1999). Impact of legislation on nursing home care in the United States: lessons for the United Kingdom.
    42. (2004). Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.
    43. (2000). Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.
    44. (2005). Metabolic syndrome and schizophrenia,
    45. (2004). Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord,
    46. (2004). Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact.
    47. (2005). Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias.
    48. (1989). Neuropsychological assessment of the severely impaired elderly patient. Clin Geriatr Med,
    49. (1976). of Mental Health. Clinical Global Impressions; Guy W.
    50. (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry,
    51. (2004). Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease,
    52. (2005). Old Age Task Force of the World Federation of Biological Psychiatry.
    53. (1997). Outcome of clozapine therapy for elderly patients with refractory primary psychosis.
    54. (2002). Patient and caregiver characteristics and nursing home placement in patients with dementia.
    55. (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
    56. (2003). Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother,
    57. (1992). Predictors of cognitive and functional progression in patients with probable Alzheimer’s disease.
    58. (2002). Probable dementia with Lewy bodies and risperidone-induced delirium.
    59. (1990). Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease
    60. (2005). Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial.
    61. (1999). Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease.
    62. (1999). Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci, 249(Suppl 8).
    63. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
    64. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials JAMA,
    65. (1998). Specific treatment of the neuroleptic malignant syndrome.
    66. (2005). Study Group on Brain Aging of the Italian Society of Gerontology and Geriatrics.
    67. (1999). The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia.
    68. (2004). The evaluation and management of patients with neuroleptic malignant syndrome.
    69. (1992). The importance of serotonin-dopamine interactions in the action of clozapine.
    70. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia,
    71. (2004). The persistence of neuropsychiatric symptoms in dementia: the Cache County Study.
    72. (2005). The quality of antipsychotic drug prescribing in nursing homes,
    73. (2004). The relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities.
    74. (2000). Thioridazine for dementia.[update
    75. (1998). Use of antipsychotic drugs in nursing homes: current compliance with OBRA regulations.
    76. (2005). Ziprasidone for agitation or psychosis in dementia: four cases.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.